Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.

Publication ,  Journal Article
Corneli, AL; McKenna, K; Perry, B; Ahmed, K; Agot, K; Malamatsho, F; Skhosana, J; Odhiambo, J; Van Damme, L
Published in: J Acquir Immune Defic Syndr
April 15, 2015

BACKGROUND: FEM-PrEP was unable to determine whether once-daily, oral emtricitabine/tenofovir disoproxil fumarate reduces the risk of HIV acquisition among women because of low adherence. Self-reported adherence was high, and pill-count data suggested good adherence. Yet, drug concentrations revealed limited pill use. We conducted a follow-up study with former participants in Bondo, Kenya, and Pretoria, South Africa, to understand factors that had influenced overreporting of adherence and to learn the whereabouts of unused pills. METHODS: Qualitative, semistructured interviews were conducted with 88 participants, and quantitative, audio computer-assisted self-interviews were conducted with 224 participants. We used thematic analysis and descriptive statistics to analyze the qualitative and quantitative data, respectively. RESULTS: In audio computer-assisted self-interviews, 31% (n = 70) said they had overreported adherence; the main reason was the belief that nonadherence would result in trial termination (69%, n = 48). A considerable percentage (35%, n = 78) acknowledged discarding unused pills. Few acknowledged giving their pills to someone else (4%, n = 10), and even fewer acknowledged giving them to someone with HIV (2%, n = 5). Many participants in the semistructured interviews said other participants had counted and removed pills from their bottles to appear adherent. CONCLUSIONS: Despite repeated messages that nonadherence would not upset staff, participants acknowledged several perceived negative consequences of reporting nonadherence, which made it difficult to report accurately. Uneasiness continued in the follow-up study, as many said they had not overreported during the trial. Efforts to improve self-reported measures should include identifying alternative methods for creating supportive environments that allow participants to feel comfortable reporting actual adherence.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Acquir Immune Defic Syndr

DOI

EISSN

1944-7884

Publication Date

April 15, 2015

Volume

68

Issue

5

Start / End Page

578 / 584

Location

United States

Related Subject Headings

  • Virology
  • Treatment Outcome
  • Tenofovir
  • South Africa
  • Organophosphonates
  • Medication Adherence
  • Kenya
  • Interviews as Topic
  • Humans
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Corneli, A. L., McKenna, K., Perry, B., Ahmed, K., Agot, K., Malamatsho, F., … Van Damme, L. (2015). The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr, 68(5), 578–584. https://doi.org/10.1097/QAI.0000000000000525
Corneli, Amy L., Kevin McKenna, Brian Perry, Khatija Ahmed, Kawango Agot, Fulufhelo Malamatsho, Joseph Skhosana, Jacob Odhiambo, and Lut Van Damme. “The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.J Acquir Immune Defic Syndr 68, no. 5 (April 15, 2015): 578–84. https://doi.org/10.1097/QAI.0000000000000525.
Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, et al. The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578–84.
Corneli, Amy L., et al. “The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.J Acquir Immune Defic Syndr, vol. 68, no. 5, Apr. 2015, pp. 578–84. Pubmed, doi:10.1097/QAI.0000000000000525.
Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, Skhosana J, Odhiambo J, Van Damme L. The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578–584.

Published In

J Acquir Immune Defic Syndr

DOI

EISSN

1944-7884

Publication Date

April 15, 2015

Volume

68

Issue

5

Start / End Page

578 / 584

Location

United States

Related Subject Headings

  • Virology
  • Treatment Outcome
  • Tenofovir
  • South Africa
  • Organophosphonates
  • Medication Adherence
  • Kenya
  • Interviews as Topic
  • Humans
  • HIV Infections